在家不准穿衣服想做就做

Cells in the small intestine play a central role in governing our immune, metabolic and neurological systems.

Our first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties.

Monoclonal microbials have been observed in preclinical models to have systemic dose-dependent effects, modulating multiple clinically validated pathways.

Our therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic diseases and cancer.

About our science

Our Platform

  • We have developed an integrated platform to develop oral biologics which harness the central role that cells in the small intestine play in governing our immune, metabolic and neurological systems.
  • The efficiency of our platform has allowed us to produce, in a relatively short period of time, product candidates for a range of inflammatory diseases and cancer.

Our Portfolio

We are advancing multiple monoclonal microbial product candidates into clinical studies across oncology and inflammatory diseases. We currently have three product candidates in clinical development, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics, including EDP1867, through preclinical development.

About our portfolio

Evelo is led by a team with deep experience.

Our leadership team has founded, led and grown transformative platform biotechnology companies. Our team has also developed and commercialized medicines that have impacted many lives.

About our team

Investors

For investor and shareholder resources, please visit the link below.

Investors page

The destination for pioneers and adventurers

If you want to join an exceptional team and culture that is committed to driving profound benefits to patients and society, let us know.

Careers page

Contact

620 Memorial Drive | 5th Floor | Cambridge, MA, 02139 USA

For general inquiries contact:
info@3g.tiantiandaan.cn

For media inquiries contact:
media@3g.tiantiandaan.cn

For investor inquiries contact:
ir@3g.tiantiandaan.cn